Prophylaxis of Fungal Invasive Infections in Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Invasive Pulmonary Aspergillosis
Interventions
DRUG

Caspofungin

"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."

Trial Locations (8)

21100

Medicina Interna I Ospedale di Circolo, Varese

25123

Divisione Ematologia Spedali Civili, Azienda Ospedaliera, Spedali Civili di Brescia, Brescia

30172

Divisione Ematologia Ospedale Umberto I, Mestre

Unknown

Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria

USC Ematologia Ospedali Riuniti di Bergamo, Bergamo

Ematologia Centro TMO - Fondazione IRCSS Ospedale Maggiore, Milan

Ematologia - TMO - Ospedale San Gerardo, Monza

Ematologia 2 - Osp. Molinette San Giovanni Battista, Torino

All Listed Sponsors
lead

Northern Italy Leukemia Group

OTHER

NCT00501098 - Prophylaxis of Fungal Invasive Infections in Leukemia | Biotech Hunter | Biotech Hunter